Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Analysts

 

Bryan, Garnier & Co: Alex Cogut

Rx Securities: Joseph Hedden

Carnegie: Arvid Necander & Erik Hultgård

Pareto Securities: Dan Akschuti

ABG Sundal Collier: Gonzalo Artiach

Redeye: Fredrik Thor

Erik Penser Bank: Ludvig Svensson

 

 

 

 

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com